Page 63 - Read Online

Calderon Novoa et al. Hepatoma Res 2023;9:33 https://dx.doi.org/10.20517/2394-5079.2023.36 Page 9 of 11

5. Dodson RM, Weiss MJ, Cosgrove D, et al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll
Surg 2013;217:736-750.e4. DOI
6. Poultsides GA, Zhu AX, Choti MA, Pawlik TM. Intrahepatic cholangiocarcinoma. Surg Clin North Am 2010;90:817-37. DOI
PubMed
7. Van Dyke AL, Shiels MS, Jones GS, et al. Biliary tract cancer incidence and trends in the United States by demographic group, 1999-
2013. Cancer 2019;125:1489-98. DOI PubMed PMC
8. Wu L, Tsilimigras DI, Paredes AZ, et al. Trends in the incidence, treatment and outcomes of patients with intrahepatic
cholangiocarcinoma in the USA: facility type is associated with margin status, use of lymphadenectomy and overall survival. World J
Surg 2019;43:1777-87. DOI
9. Xing H, Tan B, Yang C, Zhang M. Incidence trend and competing risk analysis of patients with intrahepatic cholangiocarcinoma: a
population-based study. Front Med 2022;9:846276. DOI PubMed PMC
10. Khan SA, Genus T, Morement H, Murphy A, Rous B, Tataru D. Global trends in mortality from intrahepatic and extrahepatic
cholangiocarcinoma. J Hepatol 2019;71:1261-2. DOI PubMed
11. Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol
2019;71:104-14. DOI
12. Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A
systematic review and meta-analysis. J Hepatol 2020;72:95-103. DOI PubMed
13. Petrick JL, Yang B, Altekruse SF, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a
population-based study in SEER-Medicare. PLoS One 2017;12:e0186643. DOI PubMed PMC
14. Zhou Y, Zhao Y, Li B, et al. Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis.
BMC Can-cer 2012;12:289. DOI PubMed PMC
15. Li M, Li J, Li P, et al. Hepatitis B virus infection increases the risk of cholangiocarcinoma: a meta-analysis and systematic review. J
Gastroenterol Hepatol 2012;27:1561-8. DOI
16. Chinchilla-López P, Aguilar-Olivos NE, García-Gómez J, et al. Prevalence, risk factors, and survival of patients with intrahepatic
cholangiocarcinoma. Ann Hepatol 2017;16:565-8. DOI
17. Barner-Rasmussen N, Pukkala E, Hadkhale K, Färkkilä M. Risk factors, epidemiology and prognosis of cholangiocarcinoma in
Finland. United European Gastroenterol J 2021;9:1128-35. DOI PubMed PMC
18. Izquierdo-Sanchez L, Lamarca A, La Casta A, et al. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic
insights from the ENSCCA registry. J Hepatol 2022;76:1109-21. DOI
19. Amini N, Ejaz A, Spolverato G, Kim Y, Herman JM, Pawlik TM. Temporal trends in liver-directed therapy of patients with
intrahepatic cholangiocarcinoma in the United States: a population-based analysis. J Surg Oncol 2014;110:163-70. DOI PubMed
20. Spolverato G, Vitale A, Cucchetti A, et al. Can hepatic resection provide a long-term cure for patients with intrahepatic
cholangiocarcinoma? Cancer 2015;121:3998-4006. DOI
21. Edeline J, Hirano S, Bertaut A, et al. Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary
tract cancer: combined analysis of the BCAT and PRODIGE-12 studies. Eur J Cancer 2022;164:80-7. DOI
22. Choi SH, Lee SS, Kim SY, et al. Intrahepatic cholangiocarcinoma in patients with cirrhosis: differentiation from hepatocellular
carcinoma by using gadoxetic acid-enhanced MR imaging and dynamic CT. Radiology 2017;282:771-81. DOI
23. Park S, Lee Y, Kim H, et al. Subtype classification of intrahepatic cholangiocarcinoma using liver MR imaging features and its
prognostic value. Liver Cancer 2022;11:233-46. DOI PubMed PMC
24. Rhee H, Kim MJ, Park YN, An C. A proposal of imaging classification of intrahepatic mass-forming cholangiocarcinoma into ductal
and parenchymal types: clinicopathologic significance. Eur Radiol 2019;29:3111-21. DOI
25. Seo N, Kim DY, Choi JY. Cross-Sectional imaging of intrahepatic cholangiocarcinoma: development, growth, spread, and prognosis.
AJR Am J Roentgenol 2017;209:W64-75. DOI PubMed
26. Sheng R, Wang H, Zhang Y, et al. MRI for hepatitis B-Associated intrahepatic cholangiocarcinoma: A multicenter comparative study.
J Magn Reson Imaging 2023:Online ahead of print. DOI
27. Liang B, Zhong L, He Q, et al. Diagnostic accuracy of serum CA19-9 in patients with cholangiocarcinoma: a systematic review and
meta-analysis. Med Sci Monit 2015;21:3555-63. DOI PubMed PMC
28. Wei F, Zhang JN, Zhao YQ, Lyu H, Chen F. Expression of m6A RNA methylation regulators and their clinical predictive value in
intrahepatic cholangiocarcinoma. Front Biosci 2023;28:120. DOI PubMed
29. Liang Z, Liu X, Zhang Q, Wang C, Zhao Y. Diagnostic value of microRNAs as biomarkers for cholangiocarcinoma. Dig Liver Dis
2016;48:1227-32. DOI
30. Tanaka H, Matsusaki S, Baba Y, et al. Usefulness of endoscopic transpapillary tissue sampling for malignant biliary strictures and
predictive factors of diagnostic accuracy. Clin Endosc 2018;51:174-80. DOI PubMed PMC
31. Nanda A, Brown JM, Berger SH, et al. Triple modality testing by endoscopic retrograde cholangiopancreatography for the diagnosis of
cholangiocarcinoma. Therap Adv Gastroenterol 2015;8:56-65. DOI PubMed PMC
32. Kobayashi M, Ryozawa S, Araki R, et al. Investigation of factors affecting the sensitivity of bile duct brush cytology. Intern Med
2019;58:329-35. DOI PubMed PMC
33. Kim DH, Choi DW, Choi SH, Heo JS, Kow AW. Is there a role for systematic hepatic pedicle lymphadenectomy in intrahepatic
cholangiocarcinoma? Surgery 2015;157:666-75. DOI